LOUISVILLE, Ky. – Humana Inc. HUM told the health insurance market Wednesday that it will exit additional Medicare Advantage plans for 2027, the second consecutive year the company has announced it cannot make the program’s economics work in markets where it has operated for years.
The announcement extends a retreat that has already displaced more than half a million seniors from their current Humana coverage. In late 2024, the company pulled out of thirteen service areas and more than one hundred counties for plan year 2026. Wednesday’s disclosure means the perimeter of the Medicare Advantage business Humana is willing to defend is still moving inward, not out.
The financial pressure behind both rounds of exits is the same. Humana’s medical benefit ratio – the share of premium revenue spent on actual care – has run above 90 percent in its individual Medicare Advantage segment, against company targets in the mid-80s. Every point above that threshold translates to hundreds of millions of dollars in annual losses on a program that covers millions of Americans. The company reported a significant swing to losses in the segment across 2024 and 2025 as the gap proved more durable than management had projected.
That gap is structural, rooted in how the federal government prices the program. The Centers for Medicare and Medicaid Services sets annual payment rates to private insurers based on expected medical costs, regional variation, and a quality-rating system that determines bonus payments. What those rates have not adequately captured, in Humana’s accounting and in the view of most of the managed care industry, is the persistence of post-pandemic medical utilization. Patients who deferred elective procedures and specialist visits through 2020 and 2021 did not simply absorb those deferrals. They returned for care, often with more complex conditions, and they kept returning longer than actuarial models assumed.
Across a population of seniors, whose health tends to be more fragile and whose deferred care carries higher consequence, the utilization wave was steeper and longer than the industry projected. Humana absorbed the result across 2024 and 2025 in full public view, with its Medicare Advantage segment turning from growth engine to loss center.
What the company has been doing since is finding the perimeter of the business it can sustain. That means markets where the medical cost profile is more favorable, where its provider network relationships allow better cost management, and where its star ratings are strong enough to offset ongoing cost pressure. Markets where none of those conditions meet acceptable thresholds are where Humana is withdrawing for 2027. The specific counties and service areas being exited have not been fully disclosed, and the number of additional members who will need to find new coverage will not be clear until fall enrollment data is compiled.
Chief Executive Jim Rechtin, who took over from Bruce Broussard in late 2023 as the Medicare Advantage cost crisis was becoming visible to investors, has framed the exits as deliberate portfolio discipline rather than strategic failure. A smaller Medicare Advantage business with sustainable margins, in Rechtin’s public accounting of the strategy, is worth more than a larger one generating operating losses. The argument holds so long as the exits end somewhere. A second consecutive round of market withdrawals raises the question of where that floor is.
For the seniors in affected markets, the calculation is different. Medicare Advantage plans bundle hospital, physician, and often prescription drug and dental coverage into a single product, typically at lower out-of-pocket cost than traditional Medicare with supplemental coverage. A plan exit forces re-enrollment during the Annual Enrollment Period, which runs October 15 through December 7. In markets with fewer competing insurers, the available alternatives may be limited or significantly more expensive. In some rural and lower-income counties where Humana has historically held significant market share, the options narrowed by each successive exit are not easily replaced.
Humana is not alone in the retreat. Centene Corporation’s decision in June to offer buyouts to most of its 61,000 employees – driven by Medicaid funding cuts and the expiration of ACA premium subsidies rather than Medicare Advantage specifically – illustrated that the fiscal pressure on government health programs is not confined to a single insurer or a single program. UnitedHealth Group and Elevance Health have also reported elevated medical costs in their Medicare Advantage segments, though neither has announced exits at the scale Humana has pursued across consecutive years.
Hedge funds, according to Goldman Sachs prime brokerage data from mid-July, have pushed their net exposure to US healthcare stocks to the highest level since early 2021. The managed care component of that bet assumes that CMS rate adjustments for 2027 and beyond will close enough of the reimbursement gap to return the segment to profitability. For Humana, Wednesday’s announcement signals that assumption has not yet held in enough of the company’s markets to stop the exits.
The program’s design creates a specific tension. Medicare Advantage was built to deliver better health outcomes than traditional Medicare at lower cost, with private insurers capturing a share of the savings. The theory functions when medical cost trends are stable and predictable. It breaks down when costs surge faster than the annual rate-setting process can accommodate. The 2026 and 2027 exit cycles are Humana’s successive public accounting of how severely it broke down on their book of business.
CMS has indicated it will raise Medicare Advantage payment rates for 2027. Whether those adjustments are large enough to change the math in the additional markets Humana is abandoning is the question the company’s announcement did not answer. What it answered is that, entering the 2026 Annual Enrollment Period, the list of markets where Humana has concluded they are not large enough is still growing.
